Bank of America Securities analyst Pavan Patel has reiterated their bullish stance on SUPN stock, giving a Buy rating yesterday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pavan Patel has given his Buy rating due to a combination of factors, most notably the rapid resumption of Onapgo patient starts in early 2026, which removed a key supply-related risk and unlocked a sizable backlog of demand. In addition, management’s 2026 outlook for revenues and adjusted operating earnings signals that integration benefits from the Sage acquisition and the broader CNS portfolio growth are tracking at or above expectations.
He also points to solid fourth-quarter performance, highlighted by strong double-digit growth from the company’s core neurologic and psychiatric brands, as evidence of durable underlying demand. With a healthy cash position that supports future business development in CNS and women’s health and a valuation he views as attractive relative to the earnings trajectory, Patel believes the risk‑reward profile justifies a Buy recommendation and a $65 price objective.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $65.00 price target.